论文部分内容阅读
现在有可能预测急性粒细胞性白血病患者中哪些人对常规诱导化疗有效应,哪些人将早期复发。由肿瘤组、白血病组合作进行的196名病人的前瞻性研究表明,将细胞表面标记分析法(cell surface marker analysis)用于急性粒细胞性白血病,能提供重要的预后信息,供临床使用。这种方法只需几个小时,而细胞遗传学方法需要一周左右时间。在美国白血病学会年度科学专题讨论会上,Dana Farber癌症研究所肿瘤免疫学组的James Griffin说,此研究的临床重要性在
It is now possible to predict which of the patients with acute myelogenous leukemia have effect on conventional induction chemotherapy and who will have early relapse. A prospective study of 196 patients cooperating with the tumor group and the leukemia group showed that the use of cell surface marker analysis for acute myelogenous leukemia can provide important prognostic information for clinical use. This method takes only a few hours, and the cytogenetic method takes about a week. At the annual scientific symposium of the American Leukemia Society, James Griffin of the Cancer Immunology Group at the Dana Farber Cancer Institute said that the clinical importance of this study is